Peptide Legality & Regulatory Status

In the United States, every peptide falls into one of three regulatory categories. The category — not the chemistry — determines what is legal.

The following peptides covered on this site are (or were) FDA-approved human drugs. Brand names and indications are taken from the products' DailyMed labeling or, for withdrawn products, the FDA regulatory record.

Most peptides discussed online — including BPC-157, TB-500, and ipamorelin — are sold through websites that label vials "for research purposes only" or "not for human consumption." This labeling creates the appearance of a legal loophole. Under U.S. law, it is not one.

FDA determines a product's intended use from the totality of its marketing — website claims, dosing instructions, and sales context — rather than from disclaimer text. In a February 2024 warning letter to the vendor US Chem Labs, FDA stated that despite labeling marketing its semaglutide, tirzepatide, and thymalin products as "research chemicals only" and "not for human consumption," evidence from the vendor's website established that the products were intended to be drugs for human use. FDA therefore classified them as unapproved new drugs and misbranded drugs distributed in violation of the FD&C Act.

The practical consequences of this market structure:

• Products are unapproved new drugs. No FDA review has established their safety, effectiveness, identity, purity, potency, or sterility.
• When marketed with therapeutic claims or for human use, their sale violates sections 301 and 505 of the FD&C Act. FDA enforcement tools include warning letters, product seizure, and injunctions.
• The "research use only" label has legal effect only where the sale genuinely is for laboratory research — not where the marketing context shows human use is intended.

Compounding is the only legal channel for patient use of a peptide that is not itself FDA-approved. Under section 503A, state-licensed pharmacies and physicians may compound patient-specific prescriptions; under section 503B, registered outsourcing facilities may produce larger batches under cGMP. In both cases, FDA permits compounding from a bulk drug substance only if the substance:

1. Complies with an applicable USP or National Formulary (NF) monograph;
2. Is a component of an FDA-approved drug product; or
3. Appears on FDA's list of bulk drug substances that can be used in compounding (the 503A bulks list).

While FDA develops the 503A bulks list, it applies an interim enforcement policy that sorts nominated substances into three categories. Category 1 substances may be used under the interim policy. Category 2 substances are those for which FDA has identified potential significant safety risks; FDA has said it would consider enforcement action against compounders using them. Category 3 substances were nominated with insufficient supporting information to evaluate.

BPC-157: Category 2 and the 2026 withdrawal

FDA placed BPC-157 in Category 2 in late 2023, citing potential immunogenicity risk for certain routes of administration, complexities regarding peptide-related impurities and active pharmaceutical ingredient (API) characterization, and no — or only limited — safety-related information for the proposed routes of administration. As of FDA's current listing (page updated April 22, 2026), BPC-157 appears on the agency's "nominated but withdrawn" list: the nominator withdrew the nomination, so BPC-157 is no longer in Category 2. Withdrawal is not approval — BPC-157 has not been added to the 503A bulks list and still meets none of the three compounding criteria above. Several other well-known research peptides remain in Category 2, including GHRP-2, GHRP-6, ibutamoren, ipamorelin (under 503B), and kisspeptin-10 (under 503A).

Legality and anti-doping status are separate questions. A peptide can be lawful to possess and still prohibited for any athlete subject to drug testing. The 2026 WADA Prohibited List, in effect since January 1, 2026, captures research peptides through two classes:

• S0 — Non-approved substances. Any pharmacological substance "with no current approval by any governmental regulatory health authority for human therapeutic use" is prohibited at all times, in- and out-of-competition. The class text names BPC-157 explicitly; it has been on the List since 2022. This catch-all covers essentially every unapproved research peptide, whether or not it is named.
• S2 — Peptide hormones, growth factors, related substances, and mimetics. This class prohibits growth hormone (GH), its analogues and fragments (including AOD-9604 and hGH 176-191); GHRH analogues such as CJC-1295, sermorelin, and tesamorelin; growth hormone secretagogues such as ipamorelin and ibutamoren (MK-677); GH-releasing peptides (GHRP-2, GHRP-6, and others); and growth factors including IGF-1, mechano growth factors, and thymosin-β4 and its derivatives such as TB-500.

The practical effect: nearly every research peptide covered on this site is prohibited for tested athletes at all times, regardless of its legal status in any country.

Regulatory status is jurisdiction-specific. Several peptides treated as research chemicals in the United States are approved medicines elsewhere:

• Thymosin alpha-1 (Zadaxin) is approved in over 35 countries for the treatment of hepatitis B and C and as an immune stimulant and adjuvant (PMID 19392576). It has never received FDA approval.
• Cerebrolysin, a mixture of porcine brain-derived peptides, is widely used for acute ischemic stroke in Russia, Eastern Europe, China, and other Asian and post-Soviet countries (PMID 37818733). It is not FDA-approved.
• Semax, a synthetic ACTH(4-7) analogue, is in clinical use in Russia, including administration to ischemic stroke patients in rehabilitation protocols (PMID 29798983). In the United States it is available only as a research chemical.

Approval in another country does not change U.S. status: importing an unapproved drug for personal use generally remains a violation of the FD&C Act, and the substance remains unapproved when sold domestically.